Chronic Pulmonary Aspergillosis Secondary Infection: A Case Report of <i>Achromobacter</i> spp. Lung Infection
Both pulmonary tuberculosis (PTB) and coronavirus disease-2019 (COVID-19) are risk factors for chronic pulmonary aspergillosis (CPA) and other pulmonary infectious diseases because of residual lung damage. We report a case of <i>Achromobacter</i> spp. infection following CPA in an immunocompetent woman with a history of PTB and COVID-19. A 63-year-old Cameroonian woman presented in November 2021 with a history of cough with productive muco-purulent sputum, asthenia, headaches, and chest pain for 8 weeks. There was no history of hemoptysis or difficulty in breathing. She was treated for PTB in 2002 and COVID-19 in 2020 and had no other underlying co-morbidities. Chest X-ray showed bronchiectasis in the right lung and features of healed PTB. SARS-CoV-2 antigen, antibody, and real-time polymerase chain reaction tests were negative. Microscopy and GeneXpert MTB/RIF on the sputum sample were both negative. Sputum samples grew <i>Aspergillus flavus</i> complex and <i>Aspergillus niger</i> complex, and serum <i>Aspergillus</i>-specific IgG-IgM antibody was positive, suggestive of CPA. She showed significant clinical improvement on itraconazole tablets 200 mg (every 12 h) after 4 months of therapy. She presented 1 month later with severe symptomatic relapse and elevated white blood cells (27,000 cells/μL). Antibiotic therapy with amoxicillin + clavulanic acid and subsequently with ceftriaxone was unsuccessful. Chest CT scan showed a middle right mediastinal tissue mass with crenulated edges. Bronchoalveolar lavage (BAL) and lung biopsy testing yielded a negative result for PTB, invasive aspergillosis, and lung cancer. However, the BAL sample grew <i>Achromobacter</i> spp. She was initiated on imipenem 1 g (3 g/day × 10 days) with resolution of symptoms. This case suggests that because of the high burden of TB and COVID-19 in Cameroon, pulmonary bacterial and fungal superinfections are underreported. CPA is presently undiagnosed and underreported in Cameroon. Further investigations should be performed in patients not responding to usual antibiotics.
Authors
- Felix Bongomin (ORCID: https://orcid.org/0000-0003-4515-8517)
- David W. Denning (ORCID: https://orcid.org/0000-0001-5626-2251)
- Marius Paulin Ngouanom Kuate (ORCID: https://orcid.org/0000-0003-2745-0450)
Institutions
- Gulu University (UG)
- University of Buea (CM)
- Manchester Academic Health Science Centre (GB)
- Action for ME (GB)
- University of Manchester (GB)
Publication Details
- Journal
- Clinical Case Reports
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1002/ccr3.71121
- Primary Topic
- Antifungal resistance and susceptibility
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- American Society of Tropical Medicine and Hygiene